LEADS BIOLABS-B (09887) Surges Nearly 6% Again as TCE Bispecific Antibody LBL-034 Receives FDA Fast Track Designation

Stock News01-29

LEADS BIOLABS-B (09887) rose nearly 6% again. At the time of writing, the stock was up 4.63%, trading at HK$62.2, with a turnover of HK$11.4228 million. The company announced that LBL-034, its GPRC5D/CD3 bispecific antibody independently developed based on its proprietary TCE technology platform, LeadsBody, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (RRMM). This marks another significant milestone in the product's international development path, following the FDA's Orphan Drug designation granted in October 2024, signifying further international regulatory recognition of its clinical value and development strategy. It is reported that LBL-034 is a humanized bispecific T-cell engager targeting both GPRC5D and CD3.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment